As we come to the end of 2022 and our first year as a listed company, the year in review shows a clear theme of growth and expansion across…

01/12/2023 Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces a selection of new contract wins where Optimer technology is being…

28/11/2022 Baroness Susan Greenfield opened the new site and presented on the challenges in scientific discovery Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in…

Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…

From drug screening to critical assay reagents and as targeted therapeutics, aptamers are increasingly being employed across the discovery and development pipeline. Despite the large catalogues of antibodies, aptamers and…

The ability to continuously monitor the concentration of specific molecules in the body is a long-sought goal of biomedical research. For this purpose, interstitial fluid (ISF) was proposed as…

In the age of the reproducibility crisis, working with affinity tools that offer the highest batch consistency is critical for the development of robust assays and reliable data. Aptamers,…

Why we do this. What the benefit is for you. Aptamers are increasingly being used across the life sciences in research, diagnostics and therapeutics. We have years of experience in…

After decades of research, the oligonucleotide field has reached a tipping point and is generating huge interest and momentum. Fuelling this field is the pursuit of new technologies, from…

New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…